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1. Introduction 
Alzheimer's disease (AD) is a progressive neurodegenerative disease that causes debilitating 
dementia. For yet unknown reason, AD often leads also to emotional instability. 
Neuropathologically, AD brains are characterized by the presence of extracellular fibrillar 
amyloid beta peptide (A) in amyloid plaques, intraneuronal neurofibrillary tangles 
consisting of aggregated hyperphosphorylated tau, and elevated brain levels of soluble A 
oligomers. Plaques and neurofibrillary tangles are observed mostly in the cerebral cortex, 
but subcortical regions such as nucleus basalis, thalamus, locus coeruleus and raphe nuclei 
are also affected (Price et al., 1991). The amygdala is another important subcortical region 
that is severely and consistently affected by pathology in AD. This chapter will discuss the 
neuropathological features of the amygdala affected by AD and the resulting psychological, 
emotional and cognitive disturbances in AD patients and in model mice of this disease. 
2. Emotional disturbances in AD patients 
The amygdala is part of the limbic system that plays a major role in the processing and 
memorizing of emotional reactions (Schafe et al., 2005). The involvement of the amygdala in 
emotion has been evidenced in monkeys by the overwhelming loss of normal social and 
affective behavior resulting from bilateral damage to this structure (Izquierdo et al., 2005; 
Izquierdo and Murray, 2007). The amygdala is affected early in AD and results by 
neuropsychiatric symptoms leading to functional deficits that greatly contribute to the 
disability associated with this disease. Due to the early damage to the amygdala, 
neuropsychiatric symptoms are very common in mild stages of AD. Eventually, 
approximately 80% of the patients with AD present neuropsychiatric symptoms, such as 
hallucinations, delusions, paranoia, anxiety, agitation, and affective disturbances during the 
course of their illness (Mega et al., 1996; Lyketsos et al., 2002). Other symptoms such as 
dysphoria, irritability, disinhibition and apathy are also common (Kaufer et al., 1998). In 
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addition to these symptoms, AD patients frequently show personality changes that affect 
their activities of daily living and the interaction with their caregivers. Personality changes 
may appear in any phase of dementia but often precede other early clinical manifestations of 
the disease, such as cognitive impairment and mood changes. These changes may therefore 
help in the clinical diagnosis of AD at early stages (Robins Wahlin and Byrne, 2011). 
Interestingly, personality changes and some of the neuropsychiatric symptoms (agitation, 
dysphoria and apathy) are better correlated with the severity of cognitive, functional and 
behavioral signs than with the patient’s age, gender, education or disease duration (Mega et 
al., 1996; Talassi et al., 2007). Thus, personality changes and neuropsychiatric symptoms may 
reflect the impact of progressive brain damage in AD (Robins Wahlin and Byrne, 2011). 
3. Emotional memory in AD 
Emotional memory is a form of episodic memory defined as memory of arousing emotional 
events. These memories are sometimes referred to as "flashbulb" memories (Hamann et al., 
2000). Results from studies in animals and humans have strongly implicated the amygdala 
in this memory type (LaBar, 2003; Brierley et al., 2004; Richter-Levin, 2004). While it is 
recognized that normal people better remember events associated with an emotional 
component, there is a controversy regarding the strength of emotional memory in AD 
patients (Satler et al., 2007; Schultz et al., 2009; Huijbers et al., 2011; Nashiro and Mather, 
2011; Sundstrom, 2011). Since the amygdala is one of the structures damaged in early stages 
of the AD pathology, it has been hypothesized that emotional memory should be impaired 
in AD patients. Indeed, data have shown that unlike healthy individuals, AD patients do not 
show memory enhancement for emotional events (enhanced memory for emotional 
compared to neutral stimuli) in spite of normal emotional reactions (Hamann et al., 2000). 
Notably, the degree of emotional memory impairment has positively been correlated with 
the extent of the amygdaloid atrophy (Mori et al., 1999a, b; Fleming et al., 2003).  
4. Pathology of the amygdala in AD patients 
While normal aging primarily affects the prefrontal cortex but relatively spares limbic 
regions, AD mainly affects limbic regions. The amygdala of AD patients shows a 
considerable shrinkage, distortion and loss of neurons, and widespread gliosis (Vereecken et 
al.; Herzog and Kemper, 1980; Cuenod et al., 1993). The amygdaloid atrophy in AD is the 
result of neuronal death (especially in the magnocellular basolateral amygdalar nuclei 
group) and loss of dendrites and axons. The accumulation of intraneuronal neurofibrillary 
tangles, Lewy bodies and extracellular Amyloid  peptide (A deposits in plaques also 
contribute significantly to the atrophy. Detailed pathological examination of the amygdala 
of AD patients reveals that many neurofibrillary tangles and A plaques are located in the 
accessory basal and cortical nuclei and in the cortical transition area, whereas the 
mediobasal nucleus is less affected (Kromer Vogt et al., 1990). The medial, lateral, 
laterobasal and central nuclei are relatively free of neurofibrillary tangles and A plaques 
(Kromer Vogt et al., 1990). Interestingly, it has been observed that the morphological 
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deformation of the amygdala in AD patients is associated with intrinsic damage to its 
subnuclei and their reciprocal connectivity with other brain areas. Specifically, it has been 
reported that amygdaloid nuclei receiving input from and giving rise to hippocampal 
projections are consistently affected by neuropathological alterations in AD. In contrast, 
amygdaloid nuclei which receive strong cholinergic input from nucleus basalis of Meynert 
(e.g. laterobasal nucleus) are less affected (Kromer Vogt et al., 1990). To conclude, 
histological analysis of the amygdala of AD patients allows a thorough examination of this 
region thus rendering possible to detect nucleus-specific pathologies. Nevertheless, the 
major limitation of post-mortem analysis is that it is typically performed on brains taken 
from patients at late stages of the disease. Thus, information is lacking regarding 
neuropathological alterations in early stages of AD.  
5. Imaging of the amygdala in vivo 
Whereas histological procedures are used to investigate the anatomical complexity of the 
amygdala in brains from AD patients, a standard magnetic resonance imaging (MRI) 
technique can only detect few internal details and similar resolution cannot be obtained. The 
discovery that neuronal loss is a cause of amygdaloid atrophy provided the basis for later 
studies correlating amygdaloid volumetry, as measured with MRI, with the cognitive status 
of individual AD patients. Indeed, MRI-based volumetry is now regularly used as a research 
tool to explore the relationship between amygdaloid volume and the onset and progression 
of AD (de Leon et al., 1996; Mori et al., 1999a; Vasconcelos et al., 2011). While in the past the 
use of MRI was limited to clinical studies, the recent rise in MRI accessibility allowed its 
utilization for non-clinical studies aimed at investigating the involvement of the amygdala 
in emotion, memory processes and personality (Mori et al., 1999a). The main disadvantage 
of MRI-based amygdaloid volumetry consists in the difficulty to precisely and reliably 
delineate the contours of the amygdala in vivo. This difficulty arises from the similarity 
in MRI signal intensities between the amygdala and other temporal lobe structures 
surrounding it (hippocampus proper, subiculum, entorhinal cortex, claustrum and tail of the 
caudate)(Convit et al., 1999). Nevertheless, new imaging techniques such as ultrahigh field 
structural MRI enable clear in vivo detection and even segmentation of the amygdala 
(Solano-Castiella et al., 2011), and might be used to investigate the anatomical features of 
different amygdaloid nuclei in AD patients. 
Numerous studies measuring the amygdaloid volume (normalized to intracranial volume) 
in AD patients at different clinical stages and in healthy age-matched controls showed a 
correlation of this factor with the neuropsychological performance of each patient. These 
studies have consistently demonstrated a decrease in amygdaloid volume in AD patients 
when compared to healthy controls (Horinek et al., 2007; Beacher et al., 2009; Cherubini et 
al., 2010; Lehmann et al., 2010; Vasconcelos Lde et al., 2011). Importantly, atrophy of the 
amygdala was found even in preclinical stages of the disease (Fox et al., 1996; Heun et al., 
1997; Golebiowski et al., 1999). In fact, in the very early stages of AD, amygdaloid volume 
reductions were at least as large as hippocampal volume reductions although at this stage 
 
The Amygdala – A Discrete Multitasking Manager 378 
some overlap does exist between patients and healthy controls. Still, the volume of the 
amygdala has been suggested to be an independent variable in predicting conversion from 
mild cognitive impairment to AD (Liu et al., 2010). 
Functional MRI. Increasing number of neuroimaging studies using functional MRI (fMRI) 
are used to examine the neuronal activity of the amygdala by detecting changes in local 
blood perfusion, blood volume or blood oxygenation. Injecting contrast agents are often 
used in this technique. In some studies, voxel-based morphometry (VBM) on MRI was 
combined with Positron Emission Tomography (PET) to compare activity in specific brain 
areas in AD patients and healthy controls (Kawachi et al., 2006). Functional MRI studies 
showed that the amygdala is excessively responsive to human faces (both novel emotional 
and familiar neutral expressions) in mild AD patients relative to elderly controls (Wright et 
al., 2007). On the other hand, AD patients presented deficits in the recognition of some facial 
expressions of emotion (happy, sad, fearful, and neutral expressions)(Kohler et al., 2005). 
These alterations in the normal activity of the amygdala probably contribute to the 
significant social and behavioral defects observed in AD patients.  
Positron Emission Tomography (PET). PET is almost exclusively used to image the brain, and 
may be used to detect functional abnormalities early in the course of AD, way before 
anatomical changes occur. For example, PET was used to examine acetylcholine esterase 
activity in vivo in the amygdala and cerebral cortex (Shinotoh et al., 2003). To note, levels of 
acetylcholine are significantly decreased in AD due to degeneration of the cholinergic 
magnocellular neurons of the nucleus basalis of Meynert (nbM) that send cholinergic 
projection mainly to the amygdala (Mesulam, 2004). In fact, the degree of the cholinergic 
loss is positively correlated with the severity of dementia in AD (Perry et al., 1981), probably 
due to the importance of nbM in emotional memory consolidation. PET measurements of C-
11-labeled N-methyl-4-piperidyl-acetate (MP4A, a specific substrate of AChE) have shown 
that AChE activity is significantly reduced in patients with AD in both the amygdala and 
cerebral cortex (Shinotoh et al., 2003). Importantly, these deficits are present in mild to 
moderate AD, supporting the notion that cortical and amygdaloid functional changes of the 
cholinergic system occur early in AD (Herholz et al., 2004). These functional alterations are 
therefore suggested to serve as a physiologic and noninvasive marker for certain 
neuropsychiatric manifestations of mild AD. In addition, these finding suggest that the 
amygdala should receive an important attention in studies of the mild or even prodromal 
stages of AD (Basso et al., 2006) even though considerable evidences continue to support the 
focus on the hippocampus in MRI studies of AD.   
6. The use of AD mice model to study the A-dependent changes in the 
amygdala 
In modern AD research, transgenic mice bearing infrequent mutations leading to familial 
forms of AD are being used to characterize in details the physiological, morphological and 
behavioral consequences of AD neuropathology in order to understand the anatomical and 
synaptic basis of dementia (Selkoe, 1996). These mutations include mutations in amyloid 
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precursor protein (APP), the precursor of the Aβ peptide, or in presenilin (PS) 1 or 2, the 
catalytic subunit of the gamma secretase complex, which cleaves APP to form Aβ. 
Transgenic AD mice model represents an important tool to examine the consequences of in 
vivo Aβ accumulation and were proved to mimic many of the pathological features of AD 
(Spires and Hyman, 2005; Spires-Jones and Knafo, 2012). APP and APP/PS1 mice present 
abundant extracellular Aβ plaques, synaptic dysfunction and loss, astrocytosis, activation of 
microglia and cognitive deficits (Games et al., 1995). The fact that Aβ plaques occupy a 
minor fraction (less than 5%) of the neuropil (see Fig. 1) in cognitively impaired transgenic 
mice (Knafo et al., 2009; Merino-Serrais et al., 2011) and the lack of correlation between the 
plaque load and the degree of cognitive impairment in AD patients (Terry et al., 1991; Terry, 
2000), support the notion that fibrillar Aβ in plaques does not contribute significantly to 
dementia in AD patients. Instead, soluble Aβ assemblies (i.e. oligomeric or protofibrillary 
Aβ species that linger in aqueous solution after high-speed centrifugation) seem to be the 
main factors responsible for the structural, synaptic and cognitive deficits in these mice and 
probably also in initiating disease in AD patients (Selkoe, 2002). 
 
A section stained with the anti-Aβ antibody and Nissl. 
BLA = basolateral nucleus of the amygdala; EC = external capsule; LA = lateral nucleus of the amygdala; PIR = piriform 
cortex. Scale bar, 350 m (Knafo et al., 2009) 
Figure 1. Coronal sections through the amygdala and adjacent regions showing the pattern of 
distribution of amyloid plaques.  
In a recent study, transgenic mice expressing a chimeric mouse/human amyloid precursor 
protein (Mo/HuAPP695swe) and a mutant human presenilin 1 (PS1-dE9) (APP/PS1, Borchelt 
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et al., 1997) were used to study the morphological basis for amygdala-dependent cognitive 
impairment (Knafo et al., 2009). In this study, the authors first showed a clear impairment of 
auditory fear conditioning in APP/PS1 mice, a learning task that depends on the lateral 
nucleus of the amygdala (LA) (Knafo et al., 2009). Importantly, this cognitive deficit did not 
result from changes in anxiety or sensitivity to shock. Then, the authors used intracellular 
injection of Alexa594 into projection neurons in the LA, combined with thioflavin-S plaque 
staining (Fig. 2) and three-dimensional reconstructions of the dendritic trees and spines. The 
results of this study show that in APP/PS1 mice the morphology of projection neurons in the 
amygdala is modified, as reflected by changes in dendritic complexity, and that there is a  
 
(a) Panoramic confocal (10×) views of the lateral amygdala showing Alexa594-injected neurons and thioflavin-s-
positive plaques in a Tg- mouse (left) and an APP/PS1 mouse (right).  
(b) Representative images of projection neurons from a Tg- mouse (left) and an APP/PS1 mouse (right).  
(c) The method used to distinguish dendrites and spines within and outside plaques. Left: a plaque suspected of 
containing a dendrite due to the rotation of its three-dimensional image. Center: the plaque surface is marked with the 
aid of the IsoSurface tool of Imaris software. Right: the voxels outside the surface are set to zero, leaving only the 
dendritic segment within the plaque (Knafo et al., 2009).  
Figure 2. Intracellular injections  
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significant decrease in number of large spines on these neurons (Knafo et al., 2009). The 
authors emphasized the finding that the morphological alteration in dendrites and spines 
occur mainly in plaque-free areas that occupy most of the neuropil. Thus, as spines are main 
postsynaptic elements of excitatory synapses in the brain (Gray, 1959) and are fundamental 
in memory, learning and cognition (Lamprecht and LeDoux, 2004) the authors suggested 
that these changes, rather than changes detected within plaques contribute to the cognitive 
impairment seen in APP/PS1 mice. 
To summarize, amygdala is significantly and consistently affected by A both in patients 
with AD and in mouse models of this disease. Therefore, this region is a central participant 
in the pathology of AD (Unger et al., 1991) and its damage may be the structural substrate to 
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